InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

0
Player Avatar jkok (38.06) Submitted: 5/6/2010 9:54:29 AM : Outperform Start Price: $13.01 ITMN Score: -30.64

recently suffered

Featured Broker Partners


Advertisement